诺和灵联合二甲双胍对糖尿病患者的临床效果及对血清中超敏C反应蛋白影响的观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察诺和灵联合二甲双胍对2型糖尿病的治疗效果及对血清中超敏C反应蛋白(hs-CRP)的影响，以期为临床工作提供理论支持。 方法 选择我院收治的170例2型糖尿病患者，随机分为两组。观察组85例，应用诺和灵联合二甲双胍进行治疗。对照组85例，单纯应用诺和灵进行治疗，观察两组的疗效及对血清中hs-CRP的影响。结果 两组均能有效控制血糖，但与对照组比较，观察组能明显减少诺和灵的用量[(35.30±4.14)U vs (41.24±5.31)U](P < 0.05)，并能有效降低糖化血红蛋白。两组治疗后血清中hs-CRP均下降，但是观察组血清中的下降值[(4.83±1.49)ng/L]明显高于对照组[(1.17±0.68)ng/L]。 结论 诺和灵联合二甲双胍治疗2型糖尿病患者的临床效果明显，并能减少诺和灵用量，同时有效下调血清中hs-CRP的表达，临床治疗中可以应用。
[关键词] 诺和灵；二甲双胍；2型糖尿病；超敏C反应蛋白；临床观察；效果
[中图分类号] R587.2 [文献标识码] A [文章编号] 1673-7210(2012)02(b)-0067-02
Clinical effect and hs-CRP changes of Novolin 30R combined with Metformin in the treatment of patients with type 2 diabetes
XU Jianfang
Department of Internal Medicine, Xinteng Hospital of Xiuzhou District in Jiaxing City, Zhejiang Province, Jiaxing 314015, China
[Abstract] Objective To study clinical effect and hs-CRP changes of Novolin 30R combined with Metformin in the treatment of patients with type 2 diabetes, for accumulating clinical experience and directing clinical work. Methods 170 patients of type 2 diabetes were divided into two groups. The observation group (85 cases) was treated with Novolin 30R combined with Metformin. The control group (85 cases) was treated only by Novolin 30R. The effects and impacts on hs-CRP of the two groups were observed. Results The blood sugar was controlled well in both groups. But the everyday dosage of Novolin 30R was lower in observation group than in the control group [(35.30±4.14) U vs (41.24±5.31) U] (P < 0.05). The change value of hs-CRP was obviously higher in the observation group [(4.83±1.49) ng/L] than the control group [(1.17±0.68) ng/L]. Conclusion The treatment of Novolin 30R combined with Metformin can increase the clinical effect, decrease the expression of hs-CRP, is worthy to be appilied in patients with type 2 diabetes.
[Key words] Novolin 30R; Metformin; Type 2 diabetes; Hs-CRP; Clinical observation; Effect
2型糖尿病是危害人类健康的重大疾病之一，笔者在治疗中发现，应用磺酰脲类药物治疗后，患者会出现继发性失效。继发性失效是指磺酰脲类降糖药治疗初期能有效控制血糖，长期服用后疗效持续下降，致血糖不能控制[1]，因此如何选用最佳方案是临床医生治疗的重要课题。近年有研究认为，糖尿病患者血清中急性时相蛋白的超敏C反应蛋白(hs-CRP)表达升高[2] ......
您现在查看是摘要介绍页，详见PDF附件(1911kb)。